Results 31 to 40 of about 508,637 (297)

Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices

open access: yesThrombosis Update, 2021
Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic, several highly effective and safe vaccines have been produced at remarkable speed. Following global implementation of vaccination programmes, cases of
D. Swan   +17 more
doaj   +1 more source

Coagulation

open access: yesJournal of the Royal College of Physicians of Edinburgh, 2014
The haemostatic system comprises four compartments: the vasculature, platelets, coagulation factors, and the fibrinolytic system. There is presently no laboratory or near-patient test capable of reproducing the complex regulated interaction between these four compartments.
openaire   +2 more sources

Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors

open access: yesBleeding, Thrombosis and Vascular Biology
Background: concizumab is an anti-tissue factor inhibitor monoclonal antibody designed as a once-daily subcutaneous prophylactic treatment for all hemophilia patients.
Silvia Linari   +6 more
doaj   +1 more source

Mesoglycan: Clinical Evidences for Use in Vascular Diseases

open access: yesInternational Journal of Vascular Medicine, 2010
Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions.
Antonella Tufano   +6 more
doaj   +1 more source

Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs

open access: yesInternational Journal of Vascular Medicine, 2011
Diabetes mellitus (DM) is associated with macrovascular and microvascular complications. Platelets have a “key role” in atherogenesis and its thrombotic complications in subjects with DM.
A. Tufano   +7 more
doaj   +1 more source

Tumour-associated Mucin1 correlates with the procoagulant properties of cancer cells of epithelial origin

open access: yesThrombosis Update, 2022
Background: Cancer-associated thrombosis (CAT) is caused, at least in part, by procoagulant factors produced by the tumour itself. Although MUC1 is an established biomarker for the diagnosis, immunotherapy, and prognosis of cancer, it is unclear whether ...
Yunliang Chen, Michael Scully
doaj   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye   +33 more
wiley   +1 more source

Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes

open access: yesBleeding, Thrombosis and Vascular Biology
We report three unrelated cases of Hermansky-Pudlak (HP) characterized by novel mutations in HPS3 (compound heterozygosity for c.1457G>A and c.1813G>T), HPS6 (homozygous c.210_211insGGGCC), and HPS8 (homozygous c.299dupC in BLOC1S3) genes.
Lisa Pieri   +4 more
doaj   +1 more source

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2021
Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with ...
Steven Andrew Baker   +4 more
doaj   +1 more source

Catalytic coagulation

open access: yesPhysical Review E
We introduce an autocatalytic aggregation model in which the rate at which two clusters merge to form a cluster is controlled by the presence of a third "catalytic" cluster whose mass must equal to the mass of one of the reaction partners. The catalyst is unaffected by the joining event and is available to either participate in or catalyze subsequent ...
P. L. Krapivsky, S. Redner
openaire   +3 more sources

Home - About - Disclaimer - Privacy